Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Arijit Ganguli, Dick Gourley & Shelley White-Means. (2012) Comparative Analysis of Health Care Expenditures and Presence of Mental Health Conditions of HIV-Affected Versus Non-HIV-Affected Children. Journal of HIV/AIDS & Social Services 11:3, pages 271-290.
Read now
Read now
Ann E Maloney & Linmarie Sikich. (2010) Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients. Neuropsychiatric Disease and Treatment 6, pages 749-766.
Read now
Read now
Jean A. Frazier. (2008) Introduction. Harvard Review of Psychiatry 16:2, pages 67-68.
Read now
Read now
Garry Walter, Amy Delaroche, Nerissa Soh, Glenn Hunt, Michelle Cleary, Gin Malhi, Tim Lambert, Christoph Correll & Joseph Rey. (2008) Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists. Australasian Psychiatry 16:4, pages 253-262.
Read now
Read now
Maria Deurell, Merete Weischer, Anne Katrine Pagsberg & Jette Labianca. (2008) The use of antipsychotic medication in child and adolescent psychiatric treatment in Denmark. A cross-sectional survey. Nordic Journal of Psychiatry 62:6, pages 472-480.
Read now
Read now
Vinod S. Bhatara & Rajender R. Aparasu. (2007) Pharmacotherapy with Atomoxetine for US Children and Adolescents. Annals of Clinical Psychiatry 19:3, pages 175-180.
Read now
Read now
Articles from other publishers (32)
Hankil LeeDong-Ho SongEuna HanHye-Young Kang. (2018) Nationwide Epidemiologic Study of Atypical Antipsychotic Use Among Pediatric Population with Mental Illness in Korea. Journal of Child and Adolescent Psychopharmacology 28:3, pages 205-215.
Crossref
Crossref
Shan XingTodd A. Lee. (2017) Increased Risk of Diabetes Among 6–24-Year-Olds Using Second Generation Antipsychotics. Journal of Child and Adolescent Psychopharmacology 27:9, pages 782-791.
Crossref
Crossref
Fleur M. Howells, David G. Kingdon & David S. Baldwin. (2017) Current and potential pharmacological and psychosocial interventions for anxiety symptoms and disorders in patients with schizophrenia: structured review. Human Psychopharmacology: Clinical and Experimental 32:5, pages e2628.
Crossref
Crossref
Marie-Line Menard, Susanne Thümmler, Marianna Giannitelli, Bertrand Olliac, Olivier Bonnot, David Cohen & Florence Askenazy. (2016) Incidence of adverse events in antipsychotic-naïve children and adolescents treated with antipsychotic drugs: a French multicentre naturalistic study protocol (ETAPE). BMJ Open 6:4, pages e011020.
Crossref
Crossref
G. Woods, C. Shannon, G. Davidson, K. Hoy, D. Lewis, L. Tumelty & C. Mulholland. (2015) Psychotropic prescribing patterns among adolescents in Northern Ireland presenting with psychotic symptoms during a 5-year period. Irish Journal of Psychological Medicine 33:1, pages 13-20.
Crossref
Crossref
Shinnyi Chou, Sean Jones & Ming Li. (2015) Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia. Brain Research 1618, pages 122-135.
Crossref
Crossref
M.-L. Menard, F. Askenazy, P. Auby, O. Bonnot & D. Cohen. (2015) Améliorer la surveillance de la tolérance pédiatrique des antipsychotiques en France. Archives de Pédiatrie 22:1, pages 92-97.
Crossref
Crossref
Bradley D. SteinEmily Leckman-WestinEdward Okeke, Deborah M. ScharfMark SorberoQingxian ChenKa Ho Brian ChorMolly FinnertyJennifer P. Wisdom. (2014) The Effects of Prior Authorization Policies on Medicaid-Enrolled Children's Use of Antipsychotic Medications: Evidence from Two Mid-Atlantic States. Journal of Child and Adolescent Psychopharmacology 24:7, pages 374-381.
Crossref
Crossref
Victoria Rundberg-Rivera, Richard E. Mattison, Gabrielle A. Carlson & Chenel Michel. (2014) Psychotropic Medication Use in Secondary School Special Education Students. Child and Adolescent Psychopharmacology News 19:4, pages 1-5.
Crossref
Crossref
C Cuerda, C Velasco, J Merchán-Naranjo, P García-Peris & C Arango. (2013) The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity. European Journal of Clinical Nutrition 68:2, pages 146-152.
Crossref
Crossref
Christian J. Bachmann, Thomas Lempp, Gerd Glaeske & Falk Hoffmann. (2014) Antipsychotic Prescription in Children and Adolescents. Deutsches Ärzteblatt international.
Crossref
Crossref
Andrea L Murphy, David M Gardner, Charmaine Cooke, Steve Kisely, Jean Hughes & Stan P Kutcher. (2013) Prescribing trends of antipsychotics in youth receiving income assistance: results from a retrospective population database study. BMC Psychiatry 13:1.
Crossref
Crossref
Yuan-Chang Hsu, I-Chia Chien, Happy Kuy-Lok Tan, Ching-Heng Lin, Shu-Wen Cheng, Yiing-Jenq Chou & Pesus Chou. (2013) Trends, correlates, and disease patterns of antipsychotic use among children and adolescents in Taiwan. Social Psychiatry and Psychiatric Epidemiology 48:12, pages 1889-1896.
Crossref
Crossref
Samantha Hollingworth, Michael Duhig, Wayne Hall & James Scott. (2013) National trends in the community prescribing of second-generation antipsychotic medications in Australian children and youth: the incomplete story. Australasian Psychiatry 21:5, pages 442-445.
Crossref
Crossref
Mary Pipan, Paul P. Wang & Rebecca Thompson Penna. 2013. Pediatric Drug Development. Pediatric Drug Development
355
382
.
Rebecca Ronsley, David Scott, William P Warburton, Ramsay D Hamdi, Dianna Clare Louie, Jana Davidson & Constadina Panagiotopoulos. (2013) A Population-Based Study of Antipsychotic Prescription Trends in Children and Adolescents in British Columbia, from 1996 to 2011. The Canadian Journal of Psychiatry 58:6, pages 361-369.
Crossref
Crossref
L. Oriana Linares, Nuria Martinez-Martin & F. Xavier Castellanos. (2013) Stimulant and Atypical Antipsychotic Medications For Children Placed in Foster Homes. PLoS ONE 8:1, pages e54152.
Crossref
Crossref
David M Gardner, Andrea L Murphy, Stan Kutcher, Serge Beaulieu, Carlo Carandang, Alain Labelle, Pierre Lalonde, Ashok Malla, Heather Milliken, Claire O’Donovan, Ayal Schaffer, Jorge Soni, Valerie H Taylor & Richard Williams. (2013) Evidence review and clinical guidance for the use of ziprasidone in Canada. Annals of General Psychiatry 12:1, pages 1.
Crossref
Crossref
Eiji Kirino. (2012) Efficacy and safety of aripiprazole in child and adolescent patients. European Child & Adolescent Psychiatry 21:7, pages 361-368.
Crossref
Crossref
Robert L. FindlingSarah McCue HorwitzBoris BirmaherRobert A. KowatchMary A. FristadEric A. YoungstromThomas W. FrazierDavid AxelsonNeal RyanChristine A. DemeterJudith DepewBenjamin FieldsMary Kay GillElizabeth A. DeylingBrieana M. RowlesL. Eugene Arnold. (2011) Clinical Characteristics of Children Receiving Antipsychotic Medication. Journal of Child and Adolescent Psychopharmacology 21:4, pages 311-319.
Crossref
Crossref
Alessandro Zuddas, Roberta Zanni & Tatiana Usala. (2011) Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies. European Neuropsychopharmacology 21:8, pages 600-620.
Crossref
Crossref
David Fraguas, Christoph U. Correll, Jessica Merchán-Naranjo, Marta Rapado-Castro, Mara Parellada, Carmen Moreno & Celso Arango. (2011) Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. European Neuropsychopharmacology 21:8, pages 621-645.
Crossref
Crossref
Claire Chevreuil, Elisabeth Polard, Eric Lemonnier, Paul Guillemot & Danièle Bentué-Ferrer. (2011) Prescription de l’aripiprazole chez l’enfant et l’adolescent. Therapies 66:2, pages 123-130.
Crossref
Crossref
I Kristiana, L J Sharpe, V S Catts, L H Lutze-Mann & A J Brown. (2009) Antipsychotic drugs upregulate lipogenic gene expression by disrupting intracellular trafficking of lipoprotein-derived cholesterol. The Pharmacogenomics Journal 10:5, pages 396-407.
Crossref
Crossref
Mark Olfson, Stephen Crystal, Cecilia Huang & Tobias Gerhard. (2010) Trends in Antipsychotic Drug Use by Very Young, Privately Insured Children. Journal of the American Academy of Child & Adolescent Psychiatry 49:1, pages 13-23.
Crossref
Crossref
Rajender R. Aparasu, Elda Jano & Vinod Bhatara. (2009) Concomitant antipsychotic prescribing in US outpatient settings. Research in Social and Administrative Pharmacy 5:3, pages 234-241.
Crossref
Crossref
Benedetto Vitiello, Christoph Correll, Barbara van Zwieten-Boot, Alessandro Zuddas, Mara Parellada & Celso Arango. (2009) Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. European Neuropsychopharmacology 19:9, pages 629-635.
Crossref
Crossref
Paola Rocca, Cristiana Montemagni, Filomena Castagna, Michela Giugiario, Mara Scalese & Filippo Bogetto. (2009) Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 33:2, pages 373-379.
Crossref
Crossref
Sebastian Schneeweiss & Jerry Avorn. (2009) Antipsychotic Agents and Sudden Cardiac Death — How Should We Manage the Risk?. New England Journal of Medicine 360:3, pages 294-296.
Crossref
Crossref
Anton A Subuh Surja, Kristen K Reynolds, Mark W Linder & Rif S El-Mallakh. (2008)
Pharmacogenetic testing of
CYP2D6
in patients with aripiprazole-related extrapyramidal symptoms: a case–control study
. Personalized Medicine 5:4, pages 361-365.
Crossref
Crossref
Ginger Nicol. (2008) Treating Comorbid Anxiety and Aggression in Children. Journal of the American Academy of Child & Adolescent Psychiatry 47:7, pages 833.
Crossref
Crossref
Joachim F. Hallmayer. (2007) Atypical antipsychotic medication in preschool children. Current Psychiatry Reports 9:3, pages 181-183.
Crossref
Crossref